7 Steps
Maximum: 4 CME cr.
7 new discussion posts (14 published)
Sign in to view your progression
Program Overview
Learning Objectives
Target Audience
Credit Designation
Disclosure/Disclaimer

This course will provide an overview of different types of acquired thrombocytopenia.

Participants will gain basic knowledge of platelet production and the mechanisms of thrombocytopenia;

Participants will gain an understanding of the pathogenesis of acquired thrombocytopenias and be able to establish a differential diagnosis;

Participants will gain an understanding of key concepts in the clinical and laboratory diagnosis of ITP, DITP and HIT;

Participants will gain an understanding of key concepts in the management of ITP, DITP and HIT.

This activity is intended for physicians involved in the diagnosis and management of patients who have a low platelet count. The activity will help clinicians gain familiarity with the pathogenesis of acquired thrombocytopenias and be able to establish a differential diagnosis.

Thrombocytopenia is among the most common reason for consultation with a hematologist for both in-patients and out-patients.  There are different disorders which can cause a low platelet count and put a patient at risk for bleeding. The course will help clinicians to understand the differences among the different underlying disorders and how to appropriately manage impacted patients.

CME credit for this course expired on February 25, 2020.

 

All persons in control of the content of the course have no relevant financial disclosures except:

Module 1

Tamam Bakchoul disclosed relationships with Aspen GMbH Germany, CSL-Behring and Hämostase Update as a speaker.

Module 2

Donald Arnold has disclosed relationships with Novartis and Amgen as a researcher and with Novartis, Amgen, UCB and Rigel as a consultant.

Siraj Mithoowani disclosed a relationship with Pfizer as an educational support recipient.

Cindy Neunert disclosed a relationship with Sanofi-Genzyme as a consultant.

Module 3

Yves Gruel disclosed a relationship with Aspen as a speaker and LFB as a consultant.

François Mullier disclosed relationships with Stago, Werfen, Nodia, Sysmex and Bayer as a recipient of research support. He also disclosed relationships with Boehringer Ingelheim, Bayer Healthcare, Bristol Myers Squibb and Pfizer as a speaker.

Claire Pouplard disclosed a relationship with Stago as a contractor.

Module 4

Tamam Bakchoul disclosed relationships with Aspen GMbH Germany, CSL-Behring and Hämostase Update as a speaker.

Brian Curtis disclosed a relationship with Ionis Pharmaceuticals as an advisory board member. 

In accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.

This course was partially supported by an educational grant from Dova Pharmaceuticals.

 

Personal Information form - mandatory to receive CME
Please login here or create an account to view this content.
Pre-Test
Module 1: Mechanisms of Platelet Production and Destruction
Module 2: Primary Immune Thrombocytopenia
Module 3: Heparin-Induced Thrombocytopenia
Module 4: Drug-Induced Thrombocytopenia
Post-Test, Evaluation & Certificate

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies